Heron Therapeutics | HRTX - Umsatzkosten





Umsatzkosten Veränderung Datum
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
ANI Pharmaceuticals USD 119.8M 5.3M 2026-06
Anika Therapeutics USD 11.44M 797K 2025-12
Eisai JPY 51.09B 926M 2026-06
Emergent BioSolutions USD 381.2M 226.1M 2023-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Heron Therapeutics USD 11.12M 795K 2025-12
Insmed USD 69.29M 19.79M 2026-06
Ligand Pharmaceuticals USD 11.31M 59K 2026-06
Merck USD 3.14B 200M 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Omeros USD 33.16M 18.52M 2024-06
Pacira USD 58.49M 7.75M 2026-06
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sangamo BioSciences 2.42M 1.11M 2024-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Veracyte USD 42.19M 3.7M 2026-06
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06